Allergic Respiratory Inflammation and Remodeling

Kawa A. M. Amin¹, ²

¹Department of Medical Science, Respiratory Medicine and Allergology, Clinical Chemistry and Asthma Research Centre, Uppsala University and University Hospital, Uppsala, Sweden
²Department of Microbiology/Immunology, School of Medicine, Faculty of Medical Sciences, University of Sulaimani, Sulaimani, Iraq

Abstract

Asthma and rhinitis are inflammatory diseases of the respiratory tract. Respiratory inflammation of the adaptive and innate immune system is the focus of this review, and chronic inflammation is not limited to the respiratory tissue. The inflammatory response, which consists of phagocytes, eosinophils, mast cells, and lymphocytes, spreads along the respiratory tract, leading to tissue damage. Mast cells and eosinophils are commonly recognized for their detrimental role in allergic reactions on activation through the high- and low-affinity receptors for IgE FcεRI. These cells rapidly produce and secrete many of the mediators responsible for the typical symptoms of asthma and rhinitis. However, increasing amount of evidence demonstrate that mast cells and leukocytes have vital roles in host defense against pathogenesis. Histological methods are used to study leukocytes and receptor expression pattern in different respiratory tract compartments. The overall aim of this review was to understand the relationship between upper and lower respiratory tract inflammation and remodeling in patients with allergic and non-allergic asthma and rhinitis. In conclusion, this review discusses the relationship between the upper and lower airway in respiratory disease and focuses on the effect of respiratory processes on laryngeal inflammation, remodeling, function, and symptoms; however, they also have a central role in the initiation of the allergic immune response. Our findings suggest that there are differences that contribute to the development of immunopathological mechanisms of these clinically distinct forms of asthma, rhinitis, and chronic obstructive pulmonary disease.

KEYWORDS: Respiratory tract, inflammatory cells, remodeling, allergy, asthma, rhinitis

Received: 22.05.2015  Accepted: 01.06.2015

INTRODUCTION

The principal role of the respiratory system is to permit the efficient exchange of respiratory gases (O₂ and CO₂) with the environment. The respiratory system is unique in that it is constantly exposed to a barrage of foreign substances from both the internal (at any point in time, approximately one-half of the cardiac output is received by the lungs) and external environments (with each breath, the respiratory tract is exposed to pollen, viruses, bacteria, smoke, etc.). In 2003, according to the Centers for Disease Control and Prevention, diseases of the respiratory system were the seventh and eighth leading causes of death in children aged 1–19 years [1]. Respiratory disease is the term for diseases of the respiratory system. These include diseases of the lung, pleural cavity, bronchial tubes, trachea, upper respiratory tract as well as the diseases of the nerves/muscles associated with breathing. Chronic respiratory diseases, such as asthma, chronic obstructive pulmonary disease (COPD), sarcoidosis and rhinitis, and cancer, are major components of the disease burden worldwide.

Every day, hundreds of millions of people suffer from chronic respiratory diseases. According to the latest WHO estimates (2009), currently, 300 million people have asthma and 210 million people have COPD, while millions have allergic rhinitis (AR) and other often under diagnosed chronic respiratory diseases. There is concern that deaths from asthma and rhinitis are also increasing, but the reasons for this are unclear. There is even suspicion that some asthma and rhinitis therapies may be contributing to the increase in deaths. Some readers may be excused for thinking that asthma and rhinitis are clearly defined disorders regarding which we can obtain information with confidence; however, this is far from the reality. Many of the same allergens are known to trigger allergic asthma and rhinitis. If AR is effectively treated, it could reduce asthma symptoms and may even help prevent asthma development.

Airway inflammation is initiated by stimuli at the epithelial surface, and cells already present in the tissue mediate acute inflammation. The stimuli cause activation of the resident leukocytes and structural cells to produce various cytokines, chemokines, and growth factors that cause inflammatory symptoms [2-6]. Chronic local inflammation with airway...
remodeling is observed in allergic asthma, rhinitis, and COPD; however, the location of the inflammation, the inflammatory cells involved, mediator profiles, and therapeutic response are very different [2,3,5,7,8]. This group of patients with asthma is characterized by neutrophilic inflammation, and they often experience more severe asthma that is not as steroid sensitive as allergic asthma [9]. In bronchial biopsies of patients with non-allergic asthma and rhinitis, eosinophils are scarce compared with patients with allergic asthma and rhinitis, whereas neutrophils are prominent [3,4]. Interleukin (IL)-8 appears to be the mediator of neutrophil influx because IL-8 levels are increased in sputum and connective tissue of non-allergic asthma and rhinitis and correlate to the number of neutrophils in the sputum [3,4,10].

The subsequent review focuses on common allergic conditions, including AR and asthma. This review discusses the relationship of the upper and lower airways in respiratory disease and focuses on the effect of these in terms of respiratory inflammation, remodeling, function, and symptoms.

Anatomy of the Respiratory Tract
The airway can be divided into the upper respiratory tract, which includes the nose, pharynx, and larynx, and the lower respiratory tract, which consists of the trachea, bronchi, bronchioles, and alveoli. The trachea extends from the neck to the thorax, where it divides into the right and left main bronchi, which enter the right and left lungs, respectively. Breaking up as they do into smaller bronchi and bronchioles and ending in small air sacs or alveoli, where gaseous exchange occurs.

Atopy and Asthma
Asthma is a very old disease. Although descriptions resembling asthma may be traced as far back as the 28th Century B.C., it was Aretaeus, a Greek physician, who provided the first observation of asthma as we know it today in the 2nd Century B.C.

The term “atopy” derived from the Greek word atopia (strangeness), was first used by Coca to describe a tendency to develop immediate-type hypersensitivity reactions to common allergens [11]. Genetically, allergies are associated with immunoglobulin E (IgE) antibody production and atopy, i.e., a hereditary predisposition to develop IgE specific for inhaled allergens [12], as shown by either elevated total serum IgE or allergen-specific IgE levels that are revealed by a positive radioimmunoassay test. There has been a lack of agreement on the definition of the term atopy. In the present study, we have used the definition of atopy proposed by an international consensus report. In this report, atopy was defined as a skin reaction to one or more allergens with a mean diameter of ≥3 mm and no dermatographism [13]. Affected people are sensitive to environmental allergens (e.g., pollen and house dust mites) to which most individuals are tolerant. Tolerance means that the immune system recognizes the presence of the allergen but does not react.

Asthma is a major chronic airway disorder that tends to increase in both prevalence and severity, affecting over 100 million people worldwide [14]. The disease affects people of all ages. Asthma was described many centuries ago as an attack due to sleeping in feather beds [15].

The current definition of asthma is as follows: “Asthma is a chronic inflammatory disorder of the airways in which many cells play a role in particular mast cells, eosinophils, and T-lymphocytes. In susceptible individuals, this inflammation causes recurrent episodes of wheezing, breathlessness, chest tightness, and cough, particularly at night and/or in the early morning. These symptoms are usually associated with widespread but variable airflow limitation that is at least partly reversible, either spontaneously or with treatment. The inflammation also causes an associated increase in airway responsiveness to a variety of stimuli” [16].

Asthma is clinically characterized by a highly variable and reversible obstruction of conducting airways and associated symptoms. The reversible components of airway obstructions that contribute to asthma are contractions of the smooth muscle in the airway (bronchospasm), swelling of the airway wall (edema), and the presence of increased secretions (mucus, serum proteins, and cell debris) [17]. Chronic inflammation of the airways is another characteristic of asthma. In common with certain other conditions in the respiratory tract, asthma is characterized by an enhanced ability of the airways to suddenly elicit changes in the muscle tone and bronchial secretion. This increased sensitivity that is referred to as bronchial hyperresponsiveness (BHR) is nearly ubiquitous among patients with asthma. Patients with BHR respond with an exaggerated form of bronchial obstruction when they are exposed to very low concentrations or levels of noxious chemical or physical stimuli. Patients with asthma have eosinophilia in their blood or sputum when the disease is active. It is well known that the bronchial epithelium of patients with asthma is damaged [18,19]. Eosinophils may be responsible for this tissue damage. However, the relationship between inflammation, bronchial hyperresponsiveness, and epithelial damage is not entirely clear. Our study has demonstrated that inflammatory cells may be responsible for this tissue damage (Figure 1).

Atopy is the strongest identified risk factor for the development of asthma [20]. Asthma is frequently associated with other atopic diseases, such as eczema and AR. Despite the often found connection between atopy and asthma, not all patients with asthma are atopic. A comparison of some characteristics of atopic and non-atopic asthma is given in Table 1 [21]. A few studies have compared the inflammatory response in atopic and non-atopic asthma and found both differences and resemblances. Increased levels of IL-4 and -5 were found in bronchoalveolar lavage (BAL) in both atopic and non-atopic asthma [3,22]. Differences in the secretion profile of T lymphocytes in atopic and non-atopic asthma were observed. Increased levels of IL-2 and -5 were found in non-atopic asthma, whereas in patients with atopic asthma, increased levels of IL-4 and -5 were found in BAL and in peripheral blood; in addition, sub-epithelial membranous thickening, disruption of airway epithelium, and airway inflammation associated with mucous plugging were found in atopic asthma [23]. In atopic asthma, inflammatory changes in the airway may contribute to the characteristic pathophysiological symptoms. The inflammatory
cellular infiltrate and structural changes in the mucous membrane of the airway are important factors in the development of rhinitis and asthma (Figure 1) [3,4,24]. Histological examination of the airways demonstrates diffuse infiltration of the tissue with neutrophils, eosinophils, mononuclear phagocytes, lymphocytes, mast cells, and basophilic cells. Various mediators, such as tryptase, cytokines, prostaglandins, leukotrienes, and histamine, may strongly influence immunological mechanisms either locally in the target organs or systemically in the circulation. The inflammatory process in the bronchial epithelium also includes a change from a ciliated epithelium to a non-ciliated epithelium which is also a common reaction of the epithelium to carcinogens (Figure 1, 2) [3,4].

Rhinitis

Rhinitis is defined as an inflammation of the lining of the nose that is characterized by one or more of the following symptoms: itching, sneezing, rhinorrhea, and nasal congestion. Rhinitis can be broadly classified into allergic, IgE-mediated, and non-allergic forms. AR may be further subdivided into seasonal or perennial disease. The symptoms of seasonal allergic rhinitis (SAR) are mostly triggered by an allergy to pollen. Perennial allergic rhinitis (PAR) is due to sensitivity to and contact with allergens that are present in the environment throughout the year. Symptoms of non-allergic rhinitis (NAR) may perennially occur or may be temporary in character. The symptoms of perennial non-allergic rhinitis (PNAR) can be induced by infections, such as viruses, or by non-specific triggers, such as strong smells, tobacco smoke, dust, and exhaust fumes, and by changes in environmental temperature and humidity. Moreover, PNAR can be associated with nasal polyps. Rhinitis is an illness with a prevalence of 20% in all age groups worldwide. Rhinitis is often regarded as a trivial illness; however, in reality, it affects the quality of life, causing school- and work-related dysfunction [25].

Mucosal inflammation, a characteristic of rhinitis, is associated with the accumulation of inflammatory cells (eosinophils, mast cells, basophils, lymphocytes, neutrophils, monocytes, and macrophages) in the nasal mucous membrane, as has been demonstrated in biopsy studies with regard to AR [26-28] and NAR [26-29]. The selective recruitment of mast cells and eosinophils has been demonstrated to be important in the pathogenesis of rhinitis [4,30]. Furthermore, it is known that once mast cells and eosinophils are activated, they de-granulate and release their specific mediators in SAR during the pollen season [31,32]. Similar information is available with respect to mediator release in PAR [4,31,32]. A non-allergic type of rhinitis associated with eosinophils in the secretion is the so-called non-allergic rhinitis with eosinophilia syndrome (NARES). NARES is a condition that has been recognized since 1980 [33-35] and is characterized by (1) perennial symptoms of rhinorrhea, nasal obstruction, and sneezing and (2) the appearance of high numbers of eosino-

| Table 1. Comparison of individuals with atopic and non-atopic asthma [21] |
|-----------------|-----------------|
|                 | Atopic asthma   | Non-atopic asthma |
| Asthma onset    | Childhood       | Adult             |
| Allergy         | Several         | None              |
| Family history  | Positive        | Negative          |
| Skin tests      | Positive        | Negative          |
| Serum IgE       | Specific IgE    | No specific IgE   |

Figure 1. Airway wall remodeling in allergic asthma

Figure 2. Inflammatory cells and structure change of the allergic asthma. Dark colors are mast cells, EP: epithelium; BM: basement membrane; IC: inflammatory cells; BV: blood vessel; F: fibers; SM: smooth muscle; G: gland
phils in the nasal secretion [36,37]. It has been suggested that NARES is a precursor of the aspirin triad (characterized by intrinsic asthma, nasal polyposis, and aspirin intolerance) [25,36]. The evolution of NARES appears to involve three stages: secretory eosinophilia with a healthy mucosa, eosinophilic mucosa infiltration, and in situ activation of the eosinophils. Studies regarding the degree of activation of the mediator cells in NARES are still limited. Furthermore, there is a controversy regarding the role of neutrophils in the nasal non-infectious inflammation [25,38]. There are differences between AR and NARES (Table 2) [4].

The extent of the epithelial damage in the different types of rhinitis and the correlation of the epithelial damage to the number of the various mediator cells is still not clarified. Some researchers have reported that epithelial shedding could be observed in AR [39,40] and in non-allergic rhinitis [41], whereas others have indicated that the nasal epithelium remains almost completely intact [32,42]. In AR, a chronic inflammatory disease, remodeling is still poorly understood. Although inflammation is similar in allergic rhinitis and asthma, the pathological extent of nasal remodeling and its clinical consequences may be different from those of the bronchi (Figure 3).

In asthmatic and rhinitis inflammation, eosinophils migrate from the capillary blood vessels to the epithelial cell layer of the airway wall. A cascade of events involving various activators and adhesion molecules is involved in this process. This cascade can be arbitrarily divided into four steps (Figure 3).

a) Eosinophils role along the blood vessels, mediated by reversible binding of L-selecting on eosinophils to counter structures on endothelial cells [43].
b) Cytokines and lipid mediators, which diffuse from the inflammatory site, are produced or immunobilized (e.g., PAF) by endothelial cells [44-47] as well as signaling via selectins to activate the rolling eosinophils. The shedding of L-selectin is necessary for transendothelial migration [45,47].
c) Locally produced chemoattractants, such as IL-5 [49,50], regulated on activation T cell expressed and secreted [51], eotaxin [52], and platelet-activating factor [47,53] induce a migratory response of eosinophils, which initiates transendothelial migration [54].
d) After transendothelial migration, the eosinophils move along the chemotactic gradient towards the airway wall [55,56].

<table>
<thead>
<tr>
<th>Table 2. Differentiation of allergic from non-allergic rhinitis</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Allergic rhinitis</strong></td>
</tr>
<tr>
<td>Onset of symptoms</td>
</tr>
<tr>
<td>Family history</td>
</tr>
<tr>
<td>Seasonality</td>
</tr>
<tr>
<td>Triggers</td>
</tr>
<tr>
<td>Symptoms</td>
</tr>
<tr>
<td>On examination</td>
</tr>
</tbody>
</table>

Figure 3. Eosinophils from peripheral blood to the airway wall
There are similarities and differences with regard to the inflammatory and structural changes of the nasal and bronchial mucosa in rhinitis, asthma, and COPD (Table 3).

**Role of the Bronchial and Nasal Epithelium**

The respiratory tract, from nasal cavities to the smallest bronchi, is lined by a layer of viscous mucus, which is secreted by the epithelium with the assistance of small ducted glands. Particles that touch the wall of the tract are trapped in this mucus.

The bronchial and nasal epitheliums form the interface between the respiratory system and inspired air. With the exception of the most anterior part of the nasal cavity, where a transition takes place from a cutaneous epithelium to the respiratory epithelium (and not considering the specialized olfactory region), the basic construction of the epithelium of the respiratory tract is similar from the nasal cavity to the bronchioli. The epithelial layer rests on a connective tissue substrate comprising a basement membrane (lamina propria) and submucosa, containing smooth muscle, glands, and cartilage (Figure 1). The bronchial and nasal epithelium is composed of three main cell types that together form a pseudostratified ciliated layer containing ciliated, secretory, and basal cells.

Table 3. Inflammatory and remodeling patterns in the nasal and bronchial mucosa

<table>
<thead>
<tr>
<th></th>
<th>Asthma</th>
<th>COPD</th>
<th>Rhinitis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Airway smooth muscle</td>
<td>Increase metaplasia and hyperplasia</td>
<td>Less than Asthma</td>
<td>None?</td>
</tr>
<tr>
<td>Basement membrane</td>
<td>Thickened</td>
<td>Less than asthma</td>
<td>Thin as normal</td>
</tr>
<tr>
<td>Epithelium (shedding)</td>
<td>Common, particularly in severe disease</td>
<td>Less than asthma</td>
<td>Less than asthma</td>
</tr>
<tr>
<td>Fibrosis</td>
<td>Unlikely</td>
<td>Likely</td>
<td>Unlikely</td>
</tr>
<tr>
<td>Blood Vessels (BVs)</td>
<td>Angiogenesis</td>
<td>Likely</td>
<td>Angiogenesis</td>
</tr>
<tr>
<td>Glands</td>
<td>Hypertrophy</td>
<td>Hypertrophy</td>
<td>Hypertrophy</td>
</tr>
<tr>
<td>Emphysema</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Fibroblasts</td>
<td>Increased numbers</td>
<td>Low numbers</td>
<td>Possibly increased numbers</td>
</tr>
<tr>
<td>Myofibroblasts</td>
<td>Present</td>
<td>?</td>
<td>Present</td>
</tr>
<tr>
<td>Inflammation</td>
<td>Eosinophils, mast cells, CD3, CD4/Th2, IL4, IL-5</td>
<td>Neutrophils, T cells (CD8), Macrophages, IL-8, TNF-α, CD3, CD4/Th2, IL-4, IL-5</td>
<td></td>
</tr>
</tbody>
</table>

COPD: chronic obstructive pulmonary disease

Table 4. Features of airway wall remodeling in asthma

- Thickening of the basement membrane
- The damage of the epithelium
- Increased number of fibroblast cells
- Increased number of submucous glands
- Increase in blood vessel number and area
- Smooth muscle hypertrophy and hyperplasia
- Increase in airway wall collagen
- Goblet cell hyperplasia

There are similarities and differences with regard to the inflammatory and structural changes of the nasal and bronchial mucosa in rhinitis, asthma, and COPD (Table 3).

Basal cells are considered as the stem cell of the bronchial and nasal epithelium, although there is still some uncertainty regarding this. Basal cells are pyramid-shaped cells with a small cytoplasmic/nuclear ratio. Below the basement membrane, the connective tissue compartment can be found. This compartment contains fibroblasts with their associated matrix, smooth muscle cells, seromucous glands, nerves, and capillaries. Varying numbers of granulocytes, lymphocytes, mast cells, and macrophages are observed in the stroma between seromucous glands and capillaries (Figure 2) [66-69].

Bronchial epithelial cells are part of the non-specific immune system and defend the airways against the entry of noxious substances [70]. For this defense, the integrity of the epithelial barrier, based on the presence of tight junctions between the epithelial cells, is a necessary prerequisite. In this way, the epithelium forms a physical barrier. Secretion of mucus...
and fluid in combination with ciliary activity leads to effective mucociliary clearance. The cells of the airway wall also secrete mediators, which provide protection against a range of potentially injurious agents [71].

The major differences between the nose and bronchi are that (a) the nose has venous sinuses, which largely account for nasal blockage in rhinitis, while vasodilatation is of little significance in asthma; (b) secretions can always be cleared from the nose, whereas they can plug the lower airways; and (c) smooth muscle is present around the bronchial lumen but not around the nasal cavity. Hence, the nose can be described as two congested bronchi without smooth muscle.

Epithelial integrity may also be important in preventing the penetration of inflammatory cells. Adhesion molecules and cell contacts play a crucial role in the maintenance of this integrity, and there are indications that tight junctions and/or desmosomes or hemi-desmosomes may be affected in patients with asthma [72].

Remodeling of the Respiratory Tract
Remodeling is a critical aspect of wound repair in all organs, representing a dynamic process in reaction to an inflammatory insult. Asthma is a chronic inflammatory disease of the airways, the evolution of which follows the natural course of inflammation. Chronic inflammation is always followed by healing, beginning very early and finally resulting in repair [73]. Remodeling results in a thickening of the airway wall [74], including sub-epithelial collagen deposition [75] and sub-mucosal collagen deposition [73,76]. Several patterns of airway remodeling can be found in asthma. These include smooth muscle mass increase, mucous gland enlargement, and vascular remodeling (Table 4 and Figure 1). Growth factors and cytokines are involved in these remodeling processes [3,73,77,78].

Remodeling is the collective term used to describe the structural changes observed in respiratory disease. Structural changes have been reported in a number of conditions, although they are most commonly described in the airways of patients with asthma. Results reveal that persistent airway inflammation and structural changes are associated with progressive impairment of lung function and probably nasal function. Prioritizing this area of research will be beneficial because the limited data available suggest that remodeling occurs earlier with significant long-term consequences. However, this is not an easy area of research in view of ethical and practical constraints. Therefore, efforts need to be made to maximize the opportunities for obtaining airway tissue from controls and subjects with disease. In addition, a better understanding of normal airway development is essential to accurately interpret the changes in the disease.

In conclusion, asthma and rhinitis are characterized by inflammation in the respiratory tract as well as varying degrees of structural change. In this paper, we have demonstrated the large differences in the characteristics of allergic and non-allergic asthma and rhinitis, respectively. Bronchial hyperreactivity is a phenomenon that clearly has several different etiologies. The function of the epithelial cells, increase in innervations, hypertrophy of the smooth muscles, presence of fibroblast and collagen, and increased vascularization of the blood vessels in patients with allergic asthma and allergic rhinitis could probably contribute to bronchial hypersensitivity. Leukocytes directly interact with bacteria and appear to play a vital role in host defense against pathogens. Drugs, such as glucocorticoids, cyclosporine, and cromolyn, have been demonstrated to have inhibitory effects on different cells, such as mast cell degranulation, eosinophils, neutrophils, and mediator release. This review reveals that leukocytes play an active role in such diverse disease as asthma, rhinitis, middle ear infection, and pulmonary fibrosis. Moreover, this review discusses the relationship between the upper and lower airway in respiratory disease and focuses on the effect of respiratory processes on laryngeal inflammation, remodeling, function, and symptoms; however, they also have a central role in the initiation of the allergic immune response. Our findings suggest that there are differences, participation in the development of immunopathological mechanisms of these clinically distinct forms of asthma, rhinitis, and COPD.

**Peer-review:** This manuscript was prepared by the invitation of the Editorial Board and its scientific evaluation was carried out by the Editorial Board.

**Acknowledgements:** We thank the following institution for kindly giving us permission to publish results obtained at their sites. Images of bronchial biopsies were obtained at the Department of Respiratory Medicine and Allergology and Clinical Chemistry at Uppsala University Hospital, Uppsala, Sweden. This study was supported by Bror Hjerpstedt Foundation.

**Conflict of Interest:** No conflict of interest was declared by the author.

**Financial Disclosure:** The author declared that this study has received no financial support.

**REFERENCES**

2. Amin K. The role of mast cells in allergic inflammation. Resp Med 2012;106:9-14. [CrossRef]
4. Amin K, Rinne J, Haahlela T, et al. Inflammatory cell and epithelial characteristics of perennial allergic and nonallergic rhinitis with a symptom history of 1 to 3 years’ duration. JACI 2001;107:249-57. [CrossRef]
7. Amin K, Janson C, Boman G, Venge P. The extracellular deposition of mast cell products is increased in hypertrophic airways smooth muscles in allergic asthma but not in nonallergic asthma. Allergy 2005;60:1241-7. [CrossRef]


17. Holgate ST, Roche WR, Church MK. The role of the eosinophil in asthma. Am Rev Respir Dis 1991;143(Suppl 3):66-70. [CrossRef]

18. Barnes PJ. New concepts in the pathogenesis of bronchial hyperresponsiveness and asthma. JACI 1989;83:1013-26. [CrossRef]


31. Howarth PH. The cellular basis for allergic rhinitis. Allergy 1995;50(Suppl 23):6-10. [CrossRef]

32. Rowe-Jones JM. The link between the nose and lung, perennial rhinitis and asthma—is it the same disease? Allergy 1997;52(Suppl 36):20-8. [CrossRef]

55. Endo H, Iwamoto I, Nakajima H, Yoshida S. In vitro interleukin-5 production of peripheral blood mononuclear cells is increased in patients with asthma. *Int Arch Allergy Immunol* 1993;101:425-30. [CrossRef]


64. Tsutsumi Y, Osamura RY, Watanabe K, Yanaihara N. Simultaneous immunohistochemical localization of gastrin releasing peptide (GRP) and calcitonin (CT) in human bronchial endocrine-type cells. *Virchows Arch A Pathol Anat Histopathol* 1989;37:160-6. [CrossRef]


76. Wilson JW, Li X. The measurement of reticular basement membrane and submucosal collagen in the asthmatic airway. *Clin Exp Allergy* 1997;27:363-71. [CrossRef]
